JAVIER ESTEBAN JIMÉNEZ-SALAZAR

Prof. Dr. JAVIER ESTEBAN JIMÉNEZ-SALAZAR

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2018 in Environmental Toxicology
Verified
Journal Article
Closed access
PDF file
PLPatricia López‐Arellano
Patricia López‐Arellano
KLKeila López‐Arellano
Keila López‐Arellano
JLJaquelinne Luna
Jaquelinne Luna
DMDiana Lisbeth Flores Martínez
Diana Lisbeth Flores Martínez
JAVIER ESTEBAN JIMÉNEZ-SALAZARJAVIER ESTEBAN JIMÉNEZ-SALAZAR
JAVIER ESTEBAN JIMÉNEZ-SALAZAR
EBEDMUNDO BONILLA
EDMUNDO BONILLA

26 April 2014 in Discover Oncology
Verified
Journal Article
Closed access
PDF file
JAVIER ESTEBAN JIMÉNEZ-SALAZARJAVIER ESTEBAN JIMÉNEZ-SALAZAR
JAVIER ESTEBAN JIMÉNEZ-SALAZAR
PPPedro Posadas-Rodríguez
Pedro Posadas-Rodríguez
RLRoberto Lazzarini
Roberto Lazzarini
ALArmando Luna-López
Armando Luna-López
AZAlejandro Zentella-Dehesa
Alejandro Zentella-Dehesa
PDPablo Damian-Matsumura
Pablo Damian-Matsumura

1 June 2019 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
MGMonserrat Gerardo-Ramírez
Monserrat Gerardo-Ramírez
RLRoberto Lazzarini
Roberto Lazzarini
SHSharik Hernández-Rizo
Sharik Hernández-Rizo
JAVIER ESTEBAN JIMÉNEZ-SALAZARJAVIER ESTEBAN JIMÉNEZ-SALAZAR
JAVIER ESTEBAN JIMÉNEZ-SALAZAR
ASArturo Simoni-Nieves
Arturo Simoni-Nieves
Luis Gomez-QuirozLuis Gomez-Quiroz
Luis Gomez-Quiroz

9 December 2014 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
GDG. Domínguez-Gómez
G. Domínguez-Gómez
Jose Diaz-ChavezJose Diaz-Chavez
Jose Diaz-Chavez
ACA. Chávez-Blanco
A. Chávez-Blanco
AGA. Gonzalez-Fierro
A. Gonzalez-Fierro
JAVIER ESTEBAN JIMÉNEZ-SALAZARJAVIER ESTEBAN JIMÉNEZ-SALAZAR
JAVIER ESTEBAN JIMÉNEZ-SALAZAR
ADAlfonso Dueñas-González
Alfonso Dueñas-González
Poly(ADP-ribose) polymerase (PARP) inhibitors enhance the effect of DNA alkylating agents on BRCA1‑ and BRCA2-deficient cell lines. The aim of this study was to analyze the effect of the PARP inhibitor nicotinamide (NAM) on breast cancer cells with different BRCA1 expression or function, such as BRCA1‑deficient MDA-MB-436 cells, low expression BRCA1 MCF-7 cells, and the BRCA1 wild‑type MDA-MB-231 cells, to demonstrate its effects as a chemo‑ or radiosensitizing agent. PARP activity was analyzed in MDA-MB-436, MCF-7 and MDA-MB-231 breast cancer cells subjected or not to NAM. Inhibition of PARP by NAM in the presence of DNA damage was examined by Alexa Fluor 488 immunofluorescence. Crystal violet assays were used to test growth inhibition and the chemo‑ and radiosensitization effects of NAM were investigated using clonogenic assays. Significant differences among data sets were determined using two-tailed ANOVA and Bonferroni tests. We demonstrated that NAM reduces PARP activity in vitro, and in cells subjected or not to DNA damage, it also reduces the viability of breast cancer cell lines and synergyzes the cytotoxicity of cisplatin in MDA-MB-436 and MCF-7 cells. Downregulation of PARP1 with siRNA led to modest growth inhibition, which was further increased by cisplatin. Nicotinamide also induced radiosensitization in MDA-MB-436 and MDA-MB-231 cells. In conclusion, NAM may be used as a chemo‑ or radiosensitizing agent regardless of the BRCA1 status in breast cancer.

1 May 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
CLCarlos Lara-Cruz
Carlos Lara-Cruz
JAVIER ESTEBAN JIMÉNEZ-SALAZARJAVIER ESTEBAN JIMÉNEZ-SALAZAR
JAVIER ESTEBAN JIMÉNEZ-SALAZAR
MAMarcela Arteaga-Silva
Marcela Arteaga-Silva
MAMichelle Arredondo
Michelle Arredondo
EREva Ramón-Gallegos
Eva Ramón-Gallegos
PDPablo Damian-Matsumura
Pablo Damian-Matsumura
Purpose: In the present study, we investigated the effects of 17β-estradiol (E2) on membrane roughness and gold nanoparticle (AuNP) uptake in MCF-7 breast cancer cells. Methods: Estrogen receptor (ER)-positive breast cancer cells (MCF-7) were exposed to bare 20 nm AuNPs in the presence and absence of 1×10−9 M E2 for different time intervals for up to 24 hrs. The effects of AuNP incorporation and E2 incubation on the MCF-7 cell surface roughness were measured using atomic force microscopy (AFM). Endocytic vesicle formation was studied using confocal laser scanning microscopy (CLSM). Finally, the results were confirmed by hyperspectral optical microscopy. Results: High-resolution AFM images of the surfaces of MCF-7 membranes (up to 250 nm2) were obtained. The incubation of cells for 12 hrs with AuNP and E2 increased the cell membrane roughness by 95% and 30% compared with the groups treated with vehicle (ethanol) or AuNPs only, respectively. This effect was blocked by an ER antagonist (7α,17β-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol [ICI] 182,780). Higher amounts of AuNPs were localized inside MCF-7 cells around the nucleus, even after 6 hrs of E2 incubation, compared with vehicle-treated cells. Endolysosome formation was induced by E2, which may be associated with an increase in AuNP-uptake. Conclusions: E2 enhances AuNP incorporation in MCF-7 cells by modulating of plasma membrane roughness and inducing lysosomal endocytosis. These findings provide new insights into combined nanotherapies and hormone therapies for breast cancer.

20 July 2018 in Nanomaterials
Verified
Journal Article
Open access
PDF file
ATAlexandro Téllez-Plancarte
Alexandro Téllez-Plancarte
EHEmmanuel Haro-Poniatowski
Emmanuel Haro-Poniatowski
MPMichel Picquart
Michel Picquart
JMJosé Guadalupe Morales-Méndez
José Guadalupe Morales-Méndez
CLCarlos Lara-Cruz
Carlos Lara-Cruz
NBNikola Batina
Nikola Batina
Biosensor technology has great potential for the detection of cancer through tumor-associated molecular biomarkers. In this work, we describe the immobilization of the recombinant humanized anti-HER2 monoclonal antibody (trastuzumab) on a silver nanostructured plate made by pulsed laser deposition (PLD), over a thin film of Au(111). Immobilization was performed via 4-mercapto benzoic acid self-assembled monolayers (4-MBA SAMs) that were activated with coupling reagents. A combination of immunofluorescence images and z-stack analysis by confocal laser scanning microscopy (CLSM) allowed us to detect HER2 presence and distribution in the cell membranes. Four different HER2-expressing breast cancer cell lines (SKBR3 +++, MCF-7 +/−, T47D +/−, MDA-MB-231 −) were incubated during 24 h on functionalized silver nanostructured plates (FSNP) and also on Au(111) thin films. The cells were fixed by means of an ethanol dehydration train, then characterized by atomic force microscopy (AFM) and surface-enhanced Raman scattering (SERS). SERS results showed the same tendency as CLSM findings (SKBR3 > MCF-7 > T47D > MDA-MB-231), especially when the Raman peak associated with phenylalanine amino acid (1002 cm−1) was monitored. Given the high selectivity and high sensitivity of SERS with a functionalized silver nanostructured plate (FSNP), we propose this method for identifying the presence of HER2 and consequently, of breast cancer cells.